山东大学学报(医学版) ›› 2015, Vol. 53 ›› Issue (1): 67-72.doi: 10.6040/j.issn.1671-7554.0.2014.078
马洪海, 杜贾军
MA Honghai, DU Jiajun
摘要: 目的 回顾性分析两种不同手术路径治疗胸中段食管癌的疗效。方法 研究纳入107例胸中段食管癌患者,根据手术路径不同分为两组:左胸入路组和Ivor-lewis组。采用Kaplan-Meier曲线和COX回归分析比较两组患者的生存差异,并用方差分析和非参数检验比较术后并发症、淋巴结切除情况以及其他临床因素在两组间的差异。结果 患者的一般特征、总体生存时间(P=0.315)、无复发生存时间(P=0.246)、术后胸腔总引流量(P=0.241)、淋巴结切除个数(P=0.065)、阳性淋巴结个数(P=0.188)等在两组间均无统计学差异。左胸入路组患者失血量显著少于Ivor-lewis组(P=0.007),手术时间也明显较短(P=0.042)。COX回归分析显示,T分期(P=0.001)、N分期(P=0.007)和转移淋巴结率(MLR,P=0.040)均为预后的独立危险因素。结论 Ivor-lewis和左胸入路均为胸中段食管癌手术的可选路径。
中图分类号:
[1] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917. [2] 郭梅,赵一电,杨海军,等.食管肿瘤5406例临床病理特点对比分析[J].中华肿瘤防治杂志,2008,15(1):54-56. GUO Mei, ZHAO Yidian, YANG Haijun, et al. Analysis of clinicopathological characteristics for 5406 cases of esophageal neoplasm[J]. Chin J Cancer Prev Treat, 2008, 15(1): 54-56. [3] Mao WM, Zheng WH, Ling ZQ. Epidemiologic risk factors for esophageal cancer development[J]. Asian Pac J Cancer Prev, 2011, 12(10): 2461-2466. [4] Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals[J]. Cancer, 2010, 116(16):3763-3773. [5] Casson AG, Rusch VW, Ginsberg RJ, et al. Lymph node mapping of esophageal cancer[J]. Ann Thorac Surg, 1994, 58(5): 1569-1570. [6] Mawhinney MR, Glasgow RE. Current treatment options for the management of esophageal cancer[J]. Cancer Manag Res, 2012, 4: 367-377. [7] Situ D, Wei W, Lin P, et al. Do tumor grade and location affect survival in esophageal squamous cell carcinoma? survival analysis of 302 cases of pT3N0M0 esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2013, 20(2): 580-585. [8] Yu Y, Wang Z, Liu XY, et al. Therapeutic efficacy comparison of two surgical procedures to treat middle thoracic esophageal carcinoma[J]. World J Surg, 2009, 34(2): 272-276. [9] Fox M1, Farmer R, Scoggins CR, et al. Lymph node ratio is a significant predictor of disease specific mortality in patients undergoing esophagectomy for cancer[J]. Am Surg, 2012, 78(5): 528-534. [10] Hsu WH, Hsu PK, Hsieh CC, et al. The metastatic lymph node number and ratio are independent prognostic factors in esophageal cancer[J]. J Gastrointest Surg, 2009, 13(11): 1913-1920. [11] Lee L, Sudarshan M, Li C, et al. Cost-effectiveness of minimally invasive versus open esophagectomy for esophageal cancer[J]. Ann Surg Oncol, 2013, 20(12): 3732-3739. [12] 李杰, 田锋, 林长锦, 等. 不同手术方式对胸中段食管癌的近期和远期疗效评估[J]. 实用临床医药杂志, 2013, 17(21): 50-52. LI Jie, TIAN Feng, LIN Changjin, et al. Effects of short-term and long-term evaluation of different operation methods on the middle thoracic esophageal carcinoma[J]. Journal of Clinical Medicine in Practice,2013, 17(21): 50-52. [13] 尤振兵, 徐达夫, 朱卫国, 等. 两种手术入路治疗420例胸中段食管癌的疗效比较[J]. 实用医学杂志, 2011, 27(13): 2353-2355. YOU Zhenbing, XU Dafu, ZHU Weiguo, et al. To compare the therapeutic effect of two kinds of transthoracic operative approach for 420 patients with middle thoracic esophageal cancer[J]. The Journal of Practical Medicine, 2011, 27(13): 2353-2355. [14] 罗强, 蓝碧洋, 钟醒能, 等. 两种径路治疗胸中段食管癌的手术评价[J]. 河北医学, 2012, 18(6): 746-748. [15] Song L, Liu Y, Wang Z, et al. Curative effect comparision between ivor-lewis esophagectomy and left transthoracic esophagectomy in treatment of middle thoracic esophagus carcinoma[J]. Hepatogastroenterology, 59(115): 738-741. |
[1] | 张振伟1,蒋仲敏2. Mel-18 mRNA在食管鳞癌中的表达及其临床意义[J]. 山东大学学报(医学版), 2012, 50(2): 78-. |
[2] | 孙晓宏, 庞作良, 罗洞波. MMP-2及MMP-7在食管癌及癌旁组织中的表达[J]. 山东大学学报(医学版), 2010, 48(7): 102-104. |
|